I. To evaluate the safety and tolerability of MDM2 inhibitor AMG-232 (AMG 232) in combination with standard-dose radiotherapy in soft tissue sarcoma (STS) in two separate patient cohorts (A, extremity or body wall; B, abdomen/pelvis/retroperitoneum).